12th HPAPI: Process Development for Highly Potent Drugs

Returning for the 12th Annual Year, the HPAPI: Process Development for Highly Potent Drugs Summit will provide benchmarking, clarity, and innovations, for the safe, cost efficient and quality development of hazardous materials in pharma and biotech.

The summit will bring together 100+ process scientists, chemists, engineers, and industrial hygienists from lab scale development to clinical and commercial manufacturing across hazardous small molecules and biologic-based therapeutics.

URLs:
Website: https://go.evvnt.com/1558180-0?pid=10018
Tickets: https://go.evvnt.com/1558180-2?pid=10018
Brochure: https://go.evvnt.com/1558180-3?pid=10018

Prices:
Drug Developers | Conference + 3 Workshops: USD 4196.00,
Drug Developers | Conference + 2 Workshops: USD 3697.00,
Drug Developers | Conference + 1 Workshop : USD 3198.00,
Drug Developers | Conference Only: USD 2699.00,
Solution Providers | Conference + 3 Workshops: USD 6046.00,
Solution Providers | Conference + 2 Workshops: USD 5297.00,
Solution Providers | Conference + 1 Workshop : USD 4548.00,
Solution Providers | Conference Only: USD 3799.00

Speakers: Akhil Buch | Corporate Industrial Hygienist | Hikma Pharmaceuticals, Andrew Walsh | President | Center for Pharmaceutical Cleaning Innovation, Anna Kulesza Director | CMC Pharmaceutical Development | Clovis Oncology, Brian Haney | Director, Technical Operations | Curia, David Cavalero | Senior Director Upper Providence (US) API Pilot Plant and Global Process Safety | GSK, Dean Calhoun | President and Chief Executive Officer | Affygility Solutions, Debby Santiago | EHSS Senior Manager | Amgen, Fatemeh Faghihzadeh | Senior Scientist - Upstream Process Development | Molecular Templates, Frederic Pasche | Business Developer North America | Dec Group, Ian Andrews | Senior Manager | GSK, Irfan Mohammed | CMC and Team Lead | Alexion AstraZeneca Rare Diseases, Jayen Diyora | Senior Manager, Cleaning Validation | Bristol Myers Squibb, Jie Chen | Technical Operations Manager | Abbvie, John Roosa | Associate Director/ New Technology Development and Industrial Hygiene Lead | Merck and Co, Linda Jackowiak | Associate Director SHE, Chemical Safety, Industrial Hygiene and Ergonomics | AstraZeneca, Mattia Wiedemeir | Commercial Director | Schedio, Michelle Hernandez | Director Occupational Toxicology | Merck and Co, Onkar Manjrekar | Principal Research Scientist | Abbvie, Paul Hurley | Director | Gilead Sciences, Reddy Bollu | Associate Director | Mersana Therapeutics, Rich Arnett | Manager Industrial Hygiene and Toxicology | Pharmascience, Richard Hall Hall | Committee Leader | ASTM, Robert Sussman | Managing Director | SafeBridge Regulatory and Life Sciences Group, Roee Ramot | Senior Scientist II | Novartis, Scott Patterson | Vice President Pharma/Bio Technical Support | ILC Dover, Senior Representative | WuXi STA, Srinath Thirumalairajan | Director Process Development | Seagen, William Guy | Research Associate III | Seagen

Venue details: Warwick Hotel Rittenhouse Square Philadelphia, 220 South 17th Street, Philadelphia, Pennsylvania, 19103, United States